Article Information
History
- October 22, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Raphael Ximenes, PhD1,
- Alison E. Simmons, MPH1,2,
- Gebremedhin B. Gebretekle, PhD1,
- Austin Nam, PhD1,
- Eva Wong1,
- Marina I. Salvadori1,3,
- Alyssa R. Golden, PhD4,
- Beate Sander, PhD5,6,7,8,
- Kyla J. Hildebrand9,10,
- Matthew Tunis, PhD1 and
- Ashleigh R. Tuite, PhD MPH1,2,*
- 1Centre for Immunization Surveillance and Programs, Public Health Agency of Canada, Ottawa, ON, Canada
- 2Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
- 3Department of Pediatrics, McGill University, Montreal, QC, Canada
- 4National Microbiology Laboratory Branch, Public Health Agency of Canada, Winnipeg, MB, Canada
- 5University Health Network, Toronto, ON, Canada
- 6Institute of Health Policy, Management and Evaluation (IHPME), University of Toronto, Toronto, ON, Canada
- 7Public Health Ontario, Toronto, ON, Canada
- 8ICES, Toronto, ON, Canada
- 9Department of Pediatrics, Division of Immunology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
- 10British Columbia Children’s Hospital Research Institute, Vancouver, BC, Canada
- ↵*Corresponding author Email:
raphael.ximenes{at}phac-aspc.gc.ca Funding statement: This research was supported, in part, by a Canada Research Chair in Economics of Infectious Diseases held by Beate Sander (CRC-2022-00362).
Posted October 22, 2024.
Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada
